View source for AGN-1135

{{Short description|A monoamine oxidase inhibitor and the racemic form of rasagiline}}
{{Technical|date=September 2024}}
{{Infobox drug
| drug_name =
| image = AGN-1135.svg
| width = 175px
| caption =
<!-- Clinical data -->
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| dependency_liability =
| addiction_liability =
| routes_of_administration =
| class =
| ATC_prefix =
| ATC_suffix =
<!-- Legal status -->
| legal_status =
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number = 1875-50-9
| CAS_supplemental =
| PubChem = 122316
| IUPHAR_ligand =
| DrugBank =
| ChemSpiderID = 13409715
| UNII = UZ2TR4YN26
| KEGG =
| ChEBI =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = AGN-1135; Racemic rasagiline; (±)-Rasagiline; (''RS'')-Rasagiline; ''N''-Propargyl-1-aminoindane
<!-- Chemical data -->
| IUPAC_name = ''N''-prop-2-ynyl-2,3-dihydro-1''H''-inden-1-amine
| C=12 | H=13 | N=1
| SMILES = C#CCNC1CCC2=CC=CC=C12
| StdInChI = 1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2
| StdInChIKey = RUOKEQAAGRXIBM-UHFFFAOYSA-N
}}
'''AGN-1135''' (also known as '''racemic rasagiline''' or as '''''N''-propargyl-1-aminoindane''') is a [[monoamine oxidase inhibitor]] (MAOI) that was never marketed.<ref name="Finberg2020">{{cite journal | vauthors = Finberg JP | title = The discovery and development of rasagiline as a new anti-Parkinson medication | journal = Journal of Neural Transmission | volume = 127 | issue = 2 | pages = 125–130 | date = February 2020 | pmid = 31974721 | doi = 10.1007/s00702-020-02142-w }}</ref><ref name="ChenSwope2005">{{cite journal | vauthors = Chen JJ, Swope DM | title = Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease | journal = Journal of Clinical Pharmacology | volume = 45 | issue = 8 | pages = 878–894 | date = August 2005 | pmid = 16027398 | doi = 10.1177/0091270005277935 | url = http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=16027398 | url-status = dead | s2cid = 24350277 | archive-url = https://archive.today/20120711214831/http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=16027398 | archive-date = 11 July 2012 }}</ref> It is the [[racemic mixture|racemic form]] of [[rasagiline]] and is a mixture of the ''R''(+)-[[enantiomer]] (rasagiline; TVP-1012) and ''S''(–)-enantiomer (TVP-1022).<ref name="Finberg2020" /><ref name="ChenSwope2005" /> Like rasagiline, AGN-1135 is a [[binding selectivity|selective]] [[monoamine oxidase B]] (MAO-B) [[enzyme inhibitor|inhibitor]].<ref name="Finberg2020" /> Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more [[potency (pharmacology)|potent]] as an MAO-B inhibitor than the ''S''(–)-enantiomer.<ref name="Finberg2020" /> In relation to this, [[enantiopure]] rasagiline was developed and marketed for use as a [[pharmaceutical drug]] rather than AGP-1135.<ref name="Finberg2020" />
==See also==
* [[Deprenyl]] (the racemic form of [[selegiline]])
* [[SU-11739]] (the racemic ''N''-methyl analogue of rasagiline)
* [[Desmethylselegiline]] (DMS; the ''N''-demethylated analogue of selegiline)
==References==
{{Reflist}}
{{Monoamine metabolism modulators}}
[[Category:1-Aminoindanes]]
[[Category:Abandoned drugs]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Propargyl compounds]]
{{Nervous-system-drug-stub}}